142 related articles for article (PubMed ID: 36808685)
1. Comparison of Target Pocket Similarity and Progress into Research on Inhibitors of Picornavirus 3C Proteases.
Wan L; Wang X; Wang T; Yuan X; Liu W; Huang Y; Deng C; Cao S
Chem Biodivers; 2023 Mar; 20(3):e202201100. PubMed ID: 36808685
[TBL] [Abstract][Full Text] [Related]
2. Picornaviral 3C protease inhibitors and the dual 3C protease/coronaviral 3C-like protease inhibitors.
Wang HM; Liang PH
Expert Opin Ther Pat; 2010 Jan; 20(1):59-71. PubMed ID: 20021285
[TBL] [Abstract][Full Text] [Related]
3. Structure of Senecavirus A 3C Protease Revealed the Cleavage Pattern of 3C Protease in Picornaviruses.
Meng K; Zhang L; Xue X; Xue Q; Sun M; Meng G
J Virol; 2022 Jul; 96(13):e0073622. PubMed ID: 35727031
[TBL] [Abstract][Full Text] [Related]
4. Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery.
Ramajayam R; Tan KP; Liang PH
Biochem Soc Trans; 2011 Oct; 39(5):1371-5. PubMed ID: 21936817
[TBL] [Abstract][Full Text] [Related]
5. Structural Basis for Inhibiting Porcine Epidemic Diarrhea Virus Replication with the 3C-Like Protease Inhibitor GC376.
Ye G; Wang X; Tong X; Shi Y; Fu ZF; Peng G
Viruses; 2020 Feb; 12(2):. PubMed ID: 32098094
[TBL] [Abstract][Full Text] [Related]
6. The development of Coronavirus 3C-Like protease (3CL
Liu Y; Liang C; Xin L; Ren X; Tian L; Ju X; Li H; Wang Y; Zhao Q; Liu H; Cao W; Xie X; Zhang D; Wang Y; Jian Y
Eur J Med Chem; 2020 Nov; 206():112711. PubMed ID: 32810751
[TBL] [Abstract][Full Text] [Related]
7. Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease.
Dampalla CS; Rathnayake AD; Galasiti Kankanamalage AC; Kim Y; Perera KD; Nguyen HN; Miller MJ; Madden TK; Picard HR; Thurman HA; Kashipathy MM; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
J Med Chem; 2022 Jun; 65(11):7818-7832. PubMed ID: 35638577
[TBL] [Abstract][Full Text] [Related]
8. Application of a cell-based protease assay for testing inhibitors of picornavirus 3C proteases.
van der Linden L; Ulferts R; Nabuurs SB; Kusov Y; Liu H; George S; Lacroix C; Goris N; Lefebvre D; Lanke KH; De Clercq K; Hilgenfeld R; Neyts J; van Kuppeveld FJ
Antiviral Res; 2014 Mar; 103():17-24. PubMed ID: 24393668
[TBL] [Abstract][Full Text] [Related]
9. Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites.
Iketani S; Hong SJ; Sheng J; Bahari F; Culbertson B; Atanaki FF; Aditham AK; Kratz AF; Luck MI; Tian R; Goff SP; Montazeri H; Sabo Y; Ho DD; Chavez A
Cell Host Microbe; 2022 Oct; 30(10):1354-1362.e6. PubMed ID: 36029764
[TBL] [Abstract][Full Text] [Related]
10. Individual and common inhibitors of coronavirus and picornavirus main proteases.
Kuo CJ; Liu HG; Lo YK; Seong CM; Lee KI; Jung YS; Liang PH
FEBS Lett; 2009 Feb; 583(3):549-55. PubMed ID: 19166843
[TBL] [Abstract][Full Text] [Related]
11. Toward development of generic inhibitors against the 3C proteases of picornaviruses.
Banerjee K; Bhat R; Rao VUB; Nain A; Rallapalli KL; Gangopadhyay S; Singh RP; Banerjee M; Jayaram B
FEBS J; 2019 Feb; 286(4):765-787. PubMed ID: 30461192
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of SARS-CoV 3C-like protease with baicalein.
Feng J; Li D; Zhang J; Yin X; Li J
Biochem Biophys Res Commun; 2022 Jun; 611():190-194. PubMed ID: 35490659
[TBL] [Abstract][Full Text] [Related]
13. Innate immune evasion mediated by picornaviral 3C protease: Possible lessons for coronaviral 3C-like protease?
Ng CS; Stobart CC; Luo H
Rev Med Virol; 2021 Sep; 31(5):1-22. PubMed ID: 33624382
[TBL] [Abstract][Full Text] [Related]
14. Production of a functionally active recombinant SARS-CoV-2 (COVID-19) 3C-like protease and a soluble inactive 3C-like protease-RBD chimeric in a prokaryotic expression system.
De Marco Verissimo C; López Corrales J; Dorey AL; Cwiklinski K; Lalor R; Calvani NED; Jewhurst HL; Flaus A; Doyle S; Dalton JP
Epidemiol Infect; 2022 Jun; 150():e128. PubMed ID: 35723031
[TBL] [Abstract][Full Text] [Related]
15. Novel dithiocarbamates selectively inhibit 3CL protease of SARS-CoV-2 and other coronaviruses.
Brier L; Hassan H; Hanoulle X; Landry V; Moschidi D; Desmarets L; Rouillé Y; Dumont J; Herledan A; Warenghem S; Piveteau C; Carré P; Ikherbane S; Cantrelle FX; Dupré E; Dubuisson J; Belouzard S; Leroux F; Deprez B; Charton J
Eur J Med Chem; 2023 Mar; 250():115186. PubMed ID: 36796300
[TBL] [Abstract][Full Text] [Related]
16. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL
Ma L; Li Q; Xie Y; Jianyuan Zhao ; Yi D; Guo S; Guo F; Wang J; Yang L; Cen S
Antiviral Res; 2022 Nov; 207():105419. PubMed ID: 36155070
[TBL] [Abstract][Full Text] [Related]
17. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses.
Kim Y; Lovell S; Tiew KC; Mandadapu SR; Alliston KR; Battaile KP; Groutas WC; Chang KO
J Virol; 2012 Nov; 86(21):11754-62. PubMed ID: 22915796
[TBL] [Abstract][Full Text] [Related]
18. The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate.
Wang H; Pei R; Li X; Deng W; Xing S; Zhang Y; Zhang C; He S; Sun H; Xiao S; Xiong J; Zhang Y; Chen X; Wang Y; Guo Y; Zhang B; Shang L
Eur J Med Chem; 2022 Aug; 238():114458. PubMed ID: 35635946
[TBL] [Abstract][Full Text] [Related]
19. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors.
He J; Hu L; Huang X; Wang C; Zhang Z; Wang Y; Zhang D; Ye W
Int J Antimicrob Agents; 2020 Aug; 56(2):106055. PubMed ID: 32534187
[TBL] [Abstract][Full Text] [Related]
20. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
